文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

高钾血症急诊患者使用罗库溴铵或琥珀胆碱插管:临床结局的回顾性研究

Hyperkalemic emergency department patients intubated with rocuronium or succinylcholine: Retrospective study of clinical outcomes.
PubMed 文献 · Am J Emerg Med · 2025-12-02
一句话结论高钾血症急诊患者快速序贯插管时,罗库溴铵与琥珀胆碱的24小时死亡率及1小时内心脏骤停率均无统计学显著差异。

该回顾性队列研究纳入2015年10月至2024年7月间急诊科初始血钾>5.5 mmol/L且接受快速序贯插管的成人患者434例,其中罗库溴铵组310例、琥珀胆碱组124例。主要终点24小时死亡率两组无显著差异(罗库溴铵10.0% vs 琥珀胆碱10.5%,p=0.989);次要终点1小时内心脏骤停共7例(总体1.6%),罗库溴铵组6例(1.9%)vs 琥珀胆碱组1例(0.8%,p=0.758),均未致死。回归分析显示肌松药选择与24小时死亡率无关(OR 0.911,95%CI 0.414-2.00),琥珀胆碱组中血钾水平与24小时死亡率亦无关(OR 1.311,95%CI 0.359-4.780)。作者认为研究结果对高钾血症患者选择肌松药时血钾水平的假定临床重要性提出疑问,但受回顾性设计限制。

要点

  • 高钾血症(初始血钾>5.5 mmol/L)急诊插管患者中,罗库溴铵组24小时死亡率10.0% vs 琥珀胆碱组10.5%,无统计学显著差异(p=0.989)。
  • 1小时内心脏骤停总体7例(1.6%),罗库溴铵组6例(1.9%)vs 琥珀胆碱组1例(0.8%),无统计学显著差异(p=0.758),且均未致死。
  • 回归分析显示肌松药选择与24小时死亡率无关(OR 0.911,95%CI 0.414-2.00)。
  • 琥珀胆碱组中血钾水平与24小时死亡率无关(OR 1.311,95%CI 0.359-4.780)。
  • 作者认为该研究对高钾血症患者选择肌松药时血钾水平的假定临床重要性提出疑问,但受回顾性设计限制。

适用人群与场景

  • 年龄≥18岁、2015年10月至2024年7月就诊于急诊科、初始血清钾>5.5 mmol/L并接受快速序贯插管(使用罗库溴铵或琥珀胆碱)的患者。

诊断标准与关键阈值

  • 初始血清钾>5.5 mmol/L作为高钾血症纳入阈值。

研究设计与关键结果

  • 回顾性队列研究,纳入434例患者:罗库溴铵组310例,琥珀胆碱组124例。
  • 主要终点24小时死亡率:罗库溴铵组10.0% vs 琥珀胆碱组10.5%,p=0.989,无统计学显著差异。
  • 次要终点1小时内心脏骤停:总体7例(1.6%),罗库溴铵组6例(1.9%)vs 琥珀胆碱组1例(0.8%),p=0.758,无统计学显著差异,均未致死。
  • 回归分析:肌松药选择与24小时死亡率无关(OR 0.911,95%CI 0.414-2.00)。
  • 琥珀胆碱组中血钾水平与24小时死亡率无关(OR 1.311,95%CI 0.359-4.780)。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文述及受回顾性设计限制。

对床旁实践的改变

  • 作者认为该研究对高钾血症患者选择肌松药时血钾水平的假定临床重要性提出疑问。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

STUDY OBJECTIVE: Emergency department (ED) clinicians often avoid succinylcholine due to concerns about potassium elevation leading to adverse events, though clinical evidence beyond case reports is limited. Rocuronium is a non-depolarizing paralytic that does not affect potassium levels. Therefore, it is perceived as safer despite causing longer paralysis than succinylcholine. This study aimed to compare adverse clinical outcomes in patients with pre-existing hyperkalemia who received either succinylcholine or rocuronium during rapid sequence intubation (RSI) in the ED.

METHODS: We conducted a retrospective cohort study of all ED patients aged ≥18 years presenting between October 2015 and July 2024 with initial serum potassium >5.5 mmol/L who underwent RSI with either rocuronium or succinylcholine. Data included demographics, medical history, lab values, medication administration, hospital course, and chart-reviewed details of adverse events. The primary outcome was death within 24 hours of RSI. The secondary outcome was cardiac arrest within 1 hour of RSI.

RESULTS: 434 patients were included in analysis: 310 were paralyzed with rocuronium and 124 with succinylcholine. There was no significant difference in 24-hour mortality (rocuronium 10.0%, succinylcholine 10.5%, p=0.989). Cardiac arrest within 1 hour occurred in 7 cases (1.6% overall). 6 cases were in the rocuronium group (1.9%) and 1 in the succinylcholine group (0.8%, p=0.758). None of these arrests were fatal. Regression analysis showed no association between paralytic choice and 24-hour mortality (OR 0.911, 95% CI 0.414-2.00). Among succinylcholine cases, potassium level was not associated with increased 24-hour mortality (OR 1.311, 95% CI 0.359-4.780).

CONCLUSION: We found no statistically significant difference in clinical adverse events between succinylcholine and rocuronium in hyperkalemic ED patients. While limited by its retrospective design, this study questions the presumed clinical importance of potassium levels in paralytic selection for RSI.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Simmer PE, Perza M, Cho YD, et al. Hyperkalemic emergency department patients intubated with rocuronium or succinylcholine: Retrospective study of clinical outcomes. Am J Emerg Med. 2025. PMID: 41380422. doi:10.1016/j.ajem.2025.11.030

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。